NANG KUANG PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 45.45 TWD | +1.56% |
|
+1.00% | -14.73% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 3,115 | 4,198 | 3,999 | 3,888 | 6,453 | 5,383 |
| Enterprise Value (EV) 1 | 3,412 | 4,280 | 4,214 | 4,002 | 6,460 | 5,710 |
| P/E ratio | 30.9 x | 19.3 x | 21.9 x | 19.8 x | 18.4 x | 27.2 x |
| Yield | 3.89% | 4.05% | 4.04% | 4.68% | 3.6% | 3.75% |
| Capitalization / Revenue | 2.02 x | 2.38 x | 2.28 x | 2.18 x | 3.33 x | 2.5 x |
| EV / Revenue | 2.22 x | 2.43 x | 2.4 x | 2.25 x | 3.33 x | 2.66 x |
| EV / EBITDA | 10.6 x | 9.65 x | 10.3 x | 9.24 x | 13 x | 13 x |
| EV / FCF | 27.7 x | 18.5 x | 468 x | 12 x | 33.5 x | 37.9 x |
| FCF Yield | 3.61% | 5.41% | 0.21% | 8.31% | 2.99% | 2.64% |
| Price to Book | 1.5 x | 1.94 x | 1.81 x | 1.74 x | 2.68 x | 2.26 x |
| Nbr of stocks (in thousands) | 100,988 | 100,073 | 100,989 | 100,989 | 100,989 | 100,989 |
| Reference price 2 | 30.85 | 41.95 | 39.60 | 38.50 | 63.90 | 53.30 |
| Announcement Date | 4/1/19 | 3/20/20 | 3/24/21 | 3/10/22 | 3/6/23 | 3/26/24 |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 1,539 | 1,762 | 1,755 | 1,780 | 1,940 | 2,150 |
| EBITDA 1 | 323.2 | 443.5 | 409.4 | 433.3 | 496.7 | 440.8 |
| EBIT 1 | 126.8 | 251.1 | 224.9 | 254.5 | 321.7 | 259.8 |
| Operating Margin | 8.24% | 14.25% | 12.82% | 14.3% | 16.58% | 12.08% |
| Earnings before Tax (EBT) 1 | 117.7 | 250.8 | 223.6 | 234.8 | 410.6 | 213.7 |
| Net income 1 | 101.2 | 217.4 | 183.4 | 196.1 | 352 | 198.4 |
| Net margin | 6.58% | 12.34% | 10.45% | 11.02% | 18.14% | 9.23% |
| EPS 2 | 1.000 | 2.170 | 1.810 | 1.940 | 3.480 | 1.960 |
| Free Cash Flow 1 | 123.2 | 231.8 | 9.009 | 332.7 | 193 | 150.6 |
| FCF margin | 8.01% | 13.15% | 0.51% | 18.69% | 9.94% | 7% |
| FCF Conversion (EBITDA) | 38.12% | 52.26% | 2.2% | 76.79% | 38.85% | 34.17% |
| FCF Conversion (Net income) | 121.71% | 106.58% | 4.91% | 169.67% | 54.82% | 75.91% |
| Dividend per Share 2 | 1.200 | 1.700 | 1.600 | 1.800 | 2.300 | 2.000 |
| Announcement Date | 4/1/19 | 3/20/20 | 3/24/21 | 3/10/22 | 3/6/23 | 3/26/24 |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 |
|---|---|---|---|---|
| Net sales 1 | 375.8 | 472.9 | - | 601 |
| EBITDA | - | - | - | - |
| EBIT 1 | 32.2 | 93.76 | - | 122 |
| Operating Margin | 8.57% | 19.83% | - | 20.31% |
| Earnings before Tax (EBT) | - | - | - | - |
| Net income | - | - | 74.6 | - |
| Net margin | - | - | - | - |
| EPS | - | - | 0.7400 | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 5/4/22 | 8/8/22 | 11/4/22 | 3/6/23 |
1TWD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 297 | 82.3 | 215 | 114 | 6.62 | 327 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 0.9188 x | 0.1856 x | 0.5252 x | 0.264 x | 0.0133 x | 0.7421 x |
| Free Cash Flow 1 | 123 | 232 | 9.01 | 333 | 193 | 151 |
| ROE (net income / shareholders' equity) | 4.82% | 10.3% | 8.35% | 8.82% | 15.1% | 8.29% |
| ROA (Net income/ Total Assets) | 2.49% | 4.97% | 4.29% | 4.76% | 5.73% | 4.37% |
| Assets 1 | 4,063 | 4,375 | 4,271 | 4,124 | 6,140 | 4,545 |
| Book Value Per Share 2 | 20.50 | 21.70 | 21.80 | 22.20 | 23.90 | 23.50 |
| Cash Flow per Share 2 | 1.760 | 3.880 | 2.640 | 4.130 | 3.970 | 3.750 |
| Capex 1 | 155 | 75 | 90.1 | 156 | 93.8 | 298 |
| Capex / Sales | 10.1% | 4.25% | 5.14% | 8.77% | 4.84% | 13.84% |
| Announcement Date | 4/1/19 | 3/20/20 | 3/24/21 | 3/10/22 | 3/6/23 | 3/26/24 |
1TWD in Million2TWD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -14.73% | 139M | |
| +31.16% | 695B | |
| +26.51% | 568B | |
| -4.56% | 361B | |
| +19.69% | 330B | |
| +3.88% | 283B | |
| +16.70% | 239B | |
| +8.78% | 204B | |
| -7.93% | 198B | |
| +9.00% | 168B |
- Stock Market
- Equities
- 1752 Stock
- Financials Nang Kuang Pharmaceutical Co., Ltd.